Research led by Dr. David Berman, Director of the Queen’s Cancer Research Institute and a clinician-scientist with the KGH Research Institute, has identified a simpler, faster and lower-cost approach to diagnostic testing that could rapidly improve personalized treatment of muscle-invasive bladder cancer (MIBC).
A form to help patients with a family history of cancer and their healthcare providers document a family health history. This form is for submission to the Familial Oncology Program at Kingston General Hospital.
For the referral of hereditary colorectal cancer patients to the Familial Oncology Program at Kingston General Hospital.
For the referral of patients with a suspected genetic form of cancer to the Familial Oncology Program at Kingston General Hospital.
For the referral of hereditary breast and ovarian cancer patients to the Familial Oncology Program at Kingston General Hospital.
Cutting-edge radiation therapy offers patients customized cancer care close to home
Cancer patients at Kingston General Hospital are now benefitting from a new high-tech treatment option. The Cancer Centre of Southeastern Ontario (CCSEO) at KGH has acquired a new state-of-the-art radiation therapy machine that provides specialized care to patients with complex cancers. Purchased with funding from Cancer Care Ontario, the $3-million VarianTrueBeam Linear Accelerator is one of only 14 of its kind in the province. It’s an important addition to KGH’s selection of radiation treatments, as it allows therapists to treat patients with a wider range of radiation beams that enable faster and better-targeted dose delivery for some patients, which can result in fewer radiation treatments. It is also capable of more precise radiation to treat complex tumors.